Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 128 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Follow-Up Questions
What is Oric Pharmaceuticals Inc (ORIC)'s P/E Ratio?
The P/E ratio of Oric Pharmaceuticals Inc is N/A
Who is the CEO of Oric Pharmaceuticals Inc?
Dr. Jacob Chacko is the President of Oric Pharmaceuticals Inc, joining the firm since 2018.
What is the price performance of ORIC stock?
The current price of ORIC is 11, it has increased 0.04% in the last trading day.
What are the primary business themes or industries for Oric Pharmaceuticals Inc?
Oric Pharmaceuticals Inc belongs to Biotechnology industry and the sector is Health Care
What is Oric Pharmaceuticals Inc market cap?
Oric Pharmaceuticals Inc's current market cap is $1
Is Oric Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Oric Pharmaceuticals Inc, including 9 strong buy, 8 buy, 1 hold, 0 sell, and 9 strong sell
